Initiating a discussion on laboratory-developed tests (LDTs), Dr Gottlieb asked Dr Patel to describe what LDTs are and to explain the controversy that surrounds the regulation of these diagnostic tests.
Dr Patel described LDTs as tests developed in-house by small laboratories for a specific purpose. While the FDA has not yet reached out to regulate LDTs, Dr Patel explained that CLIA or the Clinical Lab Improvement Amendments Act of 1988 is at play here. Since CLIA does not evaluate beyond the analytical validity of LDTs, it has resulted in consumers questioning the “true validity” of LDTs, she said. While many of these tests are a platform for cutting edge developments in genetics, and have widespread clinical adoption, the concern over analytical validity of these tests is a recent development, explained Dr Patel. “The FDA has released a report around this which I think is opening the door to some interesting areas,” she added.
The FDA, according to Dr Gottlieb, is using the premise that LDTs meet all the criteria of a medical device, and so need confirmation of their clinical validity but not necessarily the clinical utility. Dr Patel agreed, adding that CLIA’s role in this process would be important. For patients, it is about the reliability of a test that might indicate that you have a certain kind of predilection for a cancer, she said, and it’s the false positive or false negative results from these tests that the FDA and the media have been concerned about.
While both agreed that CMS does not have the bandwidth to undertake these regulatory roles, Dr Patel said that both the FDA’s and the CMS’ responsibilities with respect to LDTs have been under scrutiny. Dr Gottlieb added that people have also been concerned with whether the FDA has the authority to pass judgement on the clinical utility of these tests.
Dr Patel drew an analogy to the regulation of mobile applications and technologies that have applications in healthcare, indicating that while the administration may not have anticipated a role for the FDA in regulating these tests, since consumers are paying out of pocket for some of these tests, they expect more transparency at least with respect to the reliability of test results.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More